History of small-cell lung cancer

Clinical Lung Cancer

Volumn 12, Issue 2, 2011, Pages 87-93

  Haddadin, Shadi ^a   Perry, Michael C ^a  

^a UNIVERSITY OF MISSOURI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ETOPOSIDE;

CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER THERAPY; HISTORY OF MEDICINE; HUMAN; LUNG SMALL CELL CANCER; REVIEW;

EID: 79959360314     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2011.03.002     Document Type: Review

References (97)

1. Cordry HV. Tobacco: A Reference Handbook. Santa Barbara, CA: Abc-Clio Inc.; 2001.
2. Rosenblatt MB. Lung cancer in the 19th century. Bull Hist Med 1964; 38:395-425.
3. Lorenz E. Radioactivity and lung cancer; a critical review of lung cancer in the miners of Schneeberg and Joachimstal. J Natl Cancer Inst 1944; 5:1-5.
4. Onuigbo W. Lung cancer in the nineteenth century. Med Hist 1959; 3:69-77.
5. Glasser O. Wilhelm Conrad Roentgen and the Early History of the Roentgen Rays. San Francisco, CA: Norman Publishing; 1993.
6. Davies H. Recent advances in the surgery of the lung and pleura. Br J Surg 1913; 1:228-57.
7. Barnard W. The nature of the 'oat-celled sarcoma' of the mediastinum. J Pathol 1926; 29:241-4.
8. Horn L, Johnson D, Evarts A. Graham and the first pneumonectomy for lung cancer. J Clin Oncol 2008; 26:3268-75.
9. Karnofsky DA, Craver LF, Burchenal JA. The use of the nitrogen mustards in the palliative treatment of carcinoma. Cancer 1948; 1:634-56.
10. Doll R, Hill A. Smoking and carcinoma of the lung; preliminary report. BMJ 1950; 2:739-48.
11. Azzopardi JG. Oat-cell carcinoma of the bronchus. J Pathol Bacteriol 1959; 78: 513-9.
12. Zelen M. Keynote address on biostatistics and data retrieval. Cancer Chemother Rep 3 1973; 4:31-42.
13. Green RA, Humphrey E, Close H, et al. Alkylating agents in bronchogenic carcinoma. Am J Med 1969; 46:516-25.
14. Miller AB, Fox W, Tall R. Five-year follow-up of the Medical Research Council comparative trial of surgery and radiotherapy for the primary treatment of smallcelled or oat-celled carcinoma of the bronchus. Lancet 1969; 2:501-5.
15. Matthews M, Kanhouwa S, Pickren J, et al. Frequency of residual and metastatic tumor in patients undergoing curative surgical resection for lung cancer. Cancer Chemother Rep 3 1973; 4:63-7.
16. Medical Research Council Lung Cancer Working Party. Radiotherapy alone or with chemotherapy in the treatment of small-cell carcinoma of the lung. Br J Cancer 1979; 40:1-10.
17. Perry M, Eaton W, Propert K, et al. Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung. N Engl J Med 1987; 316:912-8. (Pubitemid 17041982)
18. Stahel RA, Ginsberg R, Havemann K, et al. Staging and prognostic factors in small cell lung cancer: a consensus report. Lung Cancer 1989; 5:119-26. (Pubitemid 20053516)
19. Auperin A, Arriagada R, Pignon JP, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med 1999; 341:476-84. (Pubitemid 29372887)
20. Turrisi AT 3rd, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999; 340:265-71. (Pubitemid 29063268)
21. McBurney RP, Clagett O, McDonald J. Obstructive pneumonitis secondary to bronchial adenoma. J Thorac Surg 1952; 24:411-9.
22. Watson WL, Berg J. Oat cell lung cancer. Cancer 1962; 15:759-68.
23. The World Health Organization Histological Typing of Lung Tumours. Second edition. Am J Clin Pathol 1982; 77:123-36.
24. Hirsch F, Matthews M, Aisner S, et al. Histopathologic classification of small cell lung cancer. Changing concepts and terminology. Cancer 1988; 62:973-7.
25. Mangum MD, Greco F, Hainsworth J, et al. Combined small-cell and non-smallcell lung cancer. J Clin Oncol 1989; 7:607-12. (Pubitemid 19126796)
26. Hirsch FR, Osterlind K, Hansen H. The prognostic significance of histopathologic subtyping of small cell carcinoma of the lung according to the classification of the World Health Organization. A study of 375 consecutive patients. Cancer 1983; 52:2144-50. (Pubitemid 14232260)
27. Radice PA, Matthews MJ, Ihde DC, et al. The clinical behavior of " mixed " small cell/large cell bronchogenic carcinoma compared to " pure " small cell subtypes.Cancer 1982; 50:2894-902. (Pubitemid 13220802)
28. Junker K, Wiethege T, Muller K. Pathology of small-cell lung cancer. J Cancer Res Clin Oncol 2000; 126:361-8. (Pubitemid 30436371)
29. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009; 59:225-49.
30. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006; 24:4539-44. (Pubitemid 46630948)
31. Quoix E, Fraser R, Wolkove N, et al. Small cell lung cancer presenting as a solitary pulmonary nodule. Cancer 1990; 66:577-82. (Pubitemid 20233459)
32. Livingston R, McCracken J, Trauth C, et al. Isolated pleural effusion in small cell lung carcinoma: favorable prognosis. A review of the Southwest Oncology Group experience. Chest 1982; 81:208-11. (Pubitemid 12143672)
33. Livingston R, Moore T, Heilbrun L, et al. Small-cell carcinoma of the lung: combined chemotherapy and radiation: a Southwest Oncology Group study. Ann Intern Med 1978; 88:194-9. (Pubitemid 8282151)
34. Denoix P. Enquete permanent dans les centres anticancereaux. Bull Inst Natl Hyg 1946; 1:70-5.
35. Mountain C. A new international staging system for lung cancer. Chest 1986; 89(suppl 4):225-33.
36. Shepherd F, Ginsberg R, Haddad R, et al. Importance of clinical staging in limited small-cell lung cancer: a valuable system to separate prognostic subgroups. The University of Toronto Lung Oncology Group. J Clin Oncol 1993; 11:1592-7. (Pubitemid 23228267)
37. Shepherd F. Surgery for limited stage small cell lung cancer: time to fish or cut bait. J Thorac Oncol 2010; 5:147-9.
38. Seifter E, Ihde D. Therapy of small cell lung cancer: a perspective on two decades of clinical research. Semin Oncol 1988; 15:278-99.
39. Joss R, Cavalli F, Goldhirsch A, et al. New drugs in small-cell lung cancer. Cancer Treat Rev 1986; 13:157-76. (Pubitemid 17218837)
40. Cavalli F, Sonntag R, Jungi F, et al. VP-16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules. Cancer Treat Rep 1978; 62:473-5. (Pubitemid 8335923)
41. Bunn P Jr, Cullen M, Fukuoka M, et al. Chemotherapy in small cell lung cancer: a consensus report. Lung Cancer 1989; 5:127-34. (Pubitemid 20053517)
42. Grant S, Gralla R, Kris M, et al. Single-agent chemotherapy trials in small-cell lung cancer, 1970 to 1990: the case for studies in previously treated patients. J Clin Oncol 1992; 10:484-98.
43. Smit E, Fokkema E, Biesma B, et al. A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer. Br J Cancer 1998; 77:347-51. (Pubitemid 28029555)
44. Ardizzoni A, Hansen H, Dombernowsky P, et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol 1997; 15:2090-6.
45. Masters G, Declerck L, Blanke C, et al. Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597. J Clin Oncol 2003; 21:1550-5. (Pubitemid 46594109)
46. Masuda N, Fukuoka M, Kusunoki Y, et al. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 1992; 10:1225-9.
47. Smyth J, Smith I, Sessa C, et al. Activity of docetaxel (Taxotere) in small cell lung cancer. The Early Clinical Trials Group of the EORTC. Eur J Cancer 1994; 30A: 1058-60.
48. Metro G, Cappuzzo F. Emerging drugs for small-cell lung cancer. Expert Opin Emerg Drugs 2009; 14:591-606.
49. Lowenbraun S, Bartolucci A, Smalley RV, et al. The superiority of combination chemotherapy over single agent chemotherapy in small cell lung carcinoma. Cancer 1979; 44:406-13. (Pubitemid 10220121)
50. Alberto P, Brunner K, Martz G, et al. Treatment of bronchogenic carcinoma with simultaneous or sequential combination chemotherapy, including methotrexate, cyclophosphamide, procarbazine and vincristine. Cancer 1976; 38:2208-16.
51. Einhorn L, Fee W, Farber M, et al. Improved chemotherapy for small-cell undifferentiated lung cancer. JAMA 1976; 235:1225-9.
52. Hansen H, Dombernowsky P, Hansen M, et al. Chemotherapy of advanced smallcell anaplastic carcinoma. Superiority of a four-drug combination to a three-drug combination. Ann Intern Med 1978; 89:177-81. (Pubitemid 9006077)
53. Bunn P, Greco F, Einhorn L. Cyclophosphamide, doxorubicin, and etoposide as first-line therapy in the treatment of small-cell lung cancer. Semin Oncol 1986; 13:45-53. (Pubitemid 17213295)
54. Roth B, Johnson D, Einhorn L, et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1992; 10:282-91.
55. Sundstrom S, Bremnes R, Kaasa S, et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. J Clin Oncol 2002; 20:4665-72. (Pubitemid 36025283)
56. Belcher J. Lobectomy for bronchial carcinoma. Lancet 1959; 2:639-42.
57. Fox W, Scadding J. Medical Research Council comparative trial of surgery and radiotherapy for primary treatment of small-celled or oat-celled carcinoma of bronchus. Ten-year follow-up. Lancet 1973; 2:63-5.
58. Shepherd F, Ginsberg R, Feld R, et al. Surgical treatment for limited small-cell lung cancer. The University of Toronto Lung Oncology Group experience. J Thorac Cardiovasc Surg 1991; 101:385-93.
59. Comparative trial of surgery and radiotherapy for the primary treatment of smallcelled or oat-celled carcinoma of the bronchus. First report to the Medical Research Council by the working-party on the evaluation of different methods of therapy in carcinoma of the bronchus. Lancet 1966; 2:979-86.
60. Bergsagel D, Jenkin R, Pringle J, et al. Lung cancer: clinical trial of radiotherapy alone vs. radiotherapy plus cyclophosphamide. Cancer 1972; 30:621-7.
61. Holoye P, Samuels M. Cyclophosphamide, vincristine and sequential split-course radiotherapy in the treatment of small cell lung cancer. Chest 1975; 67:675-9.
62. Byhardt R, Cox J, Holoye P, et al. The role of consolidation irradiation in combined modality therapy of small cell carcinoma of the lung. Int J Radiat Oncol Biol Phys 1982; 8:1271-6. (Pubitemid 12031974)
63. Greco FA, Brereton HD, Kent H, et al. Adriamycin and enhanced radiation reaction in normal esophagus and skin. Ann Intern Med 1976; 85:294-98.
64. Greco F, Richardson R, Snell J, et al. Small cell lung cancer. Complete remission and improved survival. Am J Med 1979; 66:625-30. (Pubitemid 9146576)
65. Trott K. Cell repopulation and overall treatment time. Int J Radiat Oncol Biol Phys 1990; 19:1071-5. (Pubitemid 20345183)
66. Daniels J, Chak L, Sikic B, et al. Chemotherapy of small-cell carcinoma of lung: a randomized comparison of alternating and sequential combination chemotherapy programs. J Clin Oncol 1984; 2:1192-9. (Pubitemid 15202691)
67. Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol 1992; 10:890-5.
68. Pignon J, Arriagada R, Ihde D, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 1992; 327:1618-24.
69. Bonner J, Sloan J, Shanahan T, et al. Phase III comparison of twice-daily splitcourse irradiation versus once-daily irradiation for patients with limited stage smallcell lung carcinoma. J Clin Oncol 1999; 17:2681-91. (Pubitemid 29415224)
70. Murray N, Coy P, Pater J, et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1993; 11:336-44. (Pubitemid 23046826)
71. Takada M, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: Results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol 2002; 20:3054-60. (Pubitemid 34791094)
72. Fried D, Morris D, Poole C, et al. Systematic Review Evaluating the Timing of Thoracic Radiation Therapy in Combined Modality Therapy for Limited-Stage Small-Cell Lung Cancer. J Clin Oncol 2004; 22:4837-45.
73. Spiro S, James L, Rudd R, et al. Early compared with late radiotherapy in combined modality treatment for limited disease small-cell lung cancer: a London Lung Cancer Group multicenter randomized clinical trial and meta-analysis. J Clin Oncol 2006; 24:3823-30. (Pubitemid 46630728)
74. Sierocki J, Hilaris B, Hopfan S, et al. cis-Dichlorodiammineplatinum(II) and VP- 16-213: an active induction regimen for small cell carcinoma of the lung. Cancer Treat Rep 1979; 63:1593-7. (Pubitemid 10167762)
75. Abratt R, Willcox P, DeGroot M, et al. Prospective study of etoposide scheduling in combination chemotherapy for limited disease small cell lung carcinoma. Eur J Cancer 1991; 27:28-30.
76. Clark P, Slevin M, Joel S, et al. A randomized trial of two etoposide schedules in small-cell lung cancer: the influence of pharmacokinetics on efficacy and toxicity. J Clin Oncol 1994; 12:1427-35. (Pubitemid 24206242)
77. Miller A, Herndon J, Hollis D, et al. Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensivestage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B. J Clin Oncol 1995; 13:1871-9.
78. Maksymiuk A, Jett J, Earle J, et al. Sequencing and schedule effects of cisplatin plus etoposide in small-cell lung cancer: results of a North Central Cancer Treatment Group randomized clinical trial. J Clin Oncol 1994; 12:70-6. (Pubitemid 24020623)
79. Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002; 346:85-91. (Pubitemid 34438898)
80. Hanna N, Bunn P, Langer C, et al. Randomized phase III trial comparing irinotecan/ cisplatin with etoposide/cisplatin in patients with previously untreated extensive- stage disease small-cell lung cancer. J Clin Oncol 2006; 24:2038-43. (Pubitemid 46622112)
81. Lara P, Shibata T, Fukuda H, et al. Cisplatin + irinotecan versus cisplatin-etoposide in extensive stage small cell lung cancer (E-SCLC): Final "common arm": comparative outcomes analysis of JCOG 9511 and SWOG 0124. [Abstract 8027] J Clin Oncol 2009; 27:15s.
82. Lara P, Redman M, Lenz H, et al. Cisplatin (Cis)/etoposide (VP16) compared to cis/irinotecan (CPT11) in extensive-stage small cell lung cancer (E-SCLC): Pharmacogenomic (PG) and comparative toxicity analysis of JCOG 9511 and SWOG 0124. [Abstract 7524] J Clin Oncol 2007; 25:7524.
83. Nugent J, Bunn P, Matthews M, et al. CNS metastases in small cell bronchogenic carcinoma: increasing frequency and changing pattern with lengthening survival. Cancer 1979; 44:1885-93. (Pubitemid 10141970)
84. Arriagada R, LeChevalier T, Borie F, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. J Natl Cancer Inst 1995; 87:183-90.
85. Shaw E, Su J, Eagan R, et al. Prophylactic cranial irradiation in complete responders with small-cell lung cancer: analysis of the Mayo Clinic and North Central Cancer Treatment Group data bases. J Clin Oncol 1994; 12:2327-32. (Pubitemid 24346703)
86. Slotman B, Faivre-Finn C, Kramer G, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 2007; 357:664-72. (Pubitemid 47267236)
87. Grosshans D, Meyers C, Allen P, et al. Neurocognitive function in patients with small cell lung cancer: effect of prophylactic cranial irradiation. Cancer 2008; 112: 589-95. (Pubitemid 351186199)
88. Komaki R, Meyers C, Shin D, et al. Evaluation of cognitive function in patients with limited small cell lung cancer prior to and shortly following prophylactic cranial irradiation. Int J Radiat Oncol Biol Phys 1995; 33:179-82.
89. Miller C, Simon K, Aslo A, et al. p53 mutations in human lung tumors. Cancer Res 1992; 52:1695-8.
90. Helin K, Holm K, Niebuhr A, et al. Loss of the retinoblastoma protein-related p130 protein in small cell lung carcinoma. Proc Natl Acad Sci U S A 1997; 94:6933-8. (Pubitemid 27281968)
91. Fong K, Sekido Y, Minna J. Molecular pathogenesis of lung cancer. J Thorac Cardiovasc Surg 1999; 118:1136-52.
92. Vestergaard J, Pedersen M, Pedersen N, et al. Hedgehog signaling in small-cell lungcancer: frequent in vivo but a rare event in vitro. Lung Cancer 2006; 52:281-90. (Pubitemid 43674545)
93. Carney D, et al. Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res 1985; 45:2913-23. (Pubitemid 15232769)
94. Pleasance E, Stephens P, O'Meara S, et al. A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 2010; 463:184-90.
95. Abidin A, Garassino M, Califano R, et al. Targeted therapies in small cell lung cancer: a review. Ther Adv Med Oncol 2010; 2:25-37.
96. Ganti A, Panwalkar A. Targeted therapy for small cell lung cancer. Target Oncol 2007; 2:89-97.
97. Blackhall F, Shepherd F. Small cell lung cancer and targeted therapies. Curr Opin Oncol 2007; 19:103-8. (Pubitemid 46204348)